Raj Bhardwaj, PhD

Dr. Bhardwaj is a pharmaceutical scientist with extensive preclinical and clinical drug discovery and development experience. That experience includes design, data analysis, interpretation & reporting of pharmacokinetics (PK)/pharmacodynamics (PD), toxicokinetic (TK), Physiological Based Pharmacokinetic (PBPK) and drug interaction studies. Dr. Bhardwaj has successfully worked in cross-functional teams including bio-analytics, biometrics, clinical development, toxicology, drug discovery and regulatory affairs for the conduct and interpretation of preclinical and clinical studies. He has provided preclinical and clinical pharmacology input into related documents including clinical development plans, protocols and amendments, Investigator Brochures, SOPs, study reports, manuscripts, summaries for regulatory authorities, IND and NDA. He has participated and presented the results in group and project meetings and building effective technical collaborations in a team model environment. Prior to joining d3 Medicine, Dr. Bhardwaj held positions at Theravance, Roche and Lundbeck. He also was a BMS/ Rutgers Research Investigator.